ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

  1. Zinzani, P.L.
  2. Mayer, J.
  3. Flowers, C.R.
  4. Bijou, F.
  5. De Oliveira, A.C.
  6. Song, Y.
  7. Zhang, Q.
  8. Merli, M.
  9. Bouabdallah, K.
  10. Ganly, P.
  11. Zhang, H.
  12. Johnson, R.
  13. Martín García-Sancho, A.
  14. Provencio Pulla, M.
  15. Trněný, M.
  16. Yuen, S.
  17. Tilly, H.
  18. Kingsley, E.
  19. Tumyan, G.
  20. Assouline, S.E.
  21. Auer, R.
  22. Ivanova, E.
  23. Kim, P.
  24. Huang, S.
  25. Delarue, R.
  26. Trotman, J.
  27. Show all authors +
Journal:
Journal of Clinical Oncology

ISSN: 1527-7755 0732-183X

Year of publication: 2023

Volume: 41

Issue: 33

Pages: 5107-5117

Type: Conference paper

DOI: 10.1200/JCO.23.00775 GOOGLE SCHOLAR lock_openOpen access editor